S Roman1,2, L Keefer1, H Imam1,3, P Korrapati1, B Mogni1, K Eident1, L Friesen1, P J Kahrilas1, Z Martinovich1, J E Pandolfino1. 1. Division of Gastroenterology and Hepatology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 2. Digestive Physiology, Hospices Civils de Lyon, Lyon I university and LabTAU Inserm 1032, Lyon, France. 3. Gastroenterology and Hepatology Unit, Department of Internal Medicine, Assiut University Hospital, Assiut, Egypt.
Abstract
BACKGROUND: Genesis of persistent gastro-esophageal reflux symptoms despite proton pump inhibitor (PPI) therapy is not fully understood. We aimed at determining reflux patterns on 24-h pH-impedance monitoring performed on PPI and correlating impedance patterns and symptom occurrence in PPI non-responders. METHODS: Seventy-eight PPI non-responder patients underwent 24-h pH-impedance monitoring on PPI. Reflux impedance characterization included gastric and supragastric belches and proximal extent of reflux. Symptoms were considered associated with reflux if occurring within 5 min after a reflux event. Patients were classified into three groups: persistent acid reflux (acid esophageal exposure [AET] >5% of time), reflux sensitivity (AET <5%, symptom index [SI] ≥50%), and functional symptoms (AET <5%, SI <50%). Dominant impedance pattern was determined for each patient. KEY RESULTS: Seven patients (9%) had persistent acid reflux, 28 (36%) reflux sensitivity, and 43 (55%) functional symptoms. A total of 4296 reflux events were identified (median per patient 45 [range 4-221]). Although liquid reflux was the most common pattern in all groups, patients with reflux sensitivity and functional symptoms had much more variability in their pattern profile with a large proportion being associated with gastric and supragastric belching. Only 417 reflux events (9.7%) were associated with symptoms. Reflux with a supragastric component and proximal extent were more likely to be associated with symptoms. CONCLUSIONS & INFERENCES: The impedance reflux profile in PPI non-responders was heterogeneous and the majority of reflux events were not associated with symptoms. Thus, the treatment of PPI non-responders should focus on mechanisms beyond reflux, such as visceral hypersensitivity and hypervigilance.
BACKGROUND: Genesis of persistent gastro-esophageal reflux symptoms despite proton pump inhibitor (PPI) therapy is not fully understood. We aimed at determining reflux patterns on 24-h pH-impedance monitoring performed on PPI and correlating impedance patterns and symptom occurrence in PPI non-responders. METHODS: Seventy-eight PPI non-responder patients underwent 24-h pH-impedance monitoring on PPI. Reflux impedance characterization included gastric and supragastric belches and proximal extent of reflux. Symptoms were considered associated with reflux if occurring within 5 min after a reflux event. Patients were classified into three groups: persistent acid reflux (acid esophageal exposure [AET] >5% of time), reflux sensitivity (AET <5%, symptom index [SI] ≥50%), and functional symptoms (AET <5%, SI <50%). Dominant impedance pattern was determined for each patient. KEY RESULTS: Seven patients (9%) had persistent acid reflux, 28 (36%) reflux sensitivity, and 43 (55%) functional symptoms. A total of 4296 reflux events were identified (median per patient 45 [range 4-221]). Although liquid reflux was the most common pattern in all groups, patients with reflux sensitivity and functional symptoms had much more variability in their pattern profile with a large proportion being associated with gastric and supragastric belching. Only 417 reflux events (9.7%) were associated with symptoms. Reflux with a supragastric component and proximal extent were more likely to be associated with symptoms. CONCLUSIONS & INFERENCES: The impedance reflux profile in PPI non-responders was heterogeneous and the majority of reflux events were not associated with symptoms. Thus, the treatment of PPI non-responders should focus on mechanisms beyond reflux, such as visceral hypersensitivity and hypervigilance.
Authors: Guy E Boeckxstaens; Hanneke Beaumont; Jan G Hatlebakk; Debra G Silberg; Karin Björck; Maria Karlsson; Hans Denison Journal: Gut Date: 2011-03-14 Impact factor: 23.059
Authors: P J Kahrilas; A J Bredenoord; M Fox; C P Gyawali; S Roman; A J P M Smout; J E Pandolfino Journal: Neurogastroenterol Motil Date: 2014-12-03 Impact factor: 3.598
Authors: T H Taft; J R Triggs; D A Carlson; L Guadagnoli; K N Tomasino; L Keefer; J E Pandolfino Journal: Aliment Pharmacol Ther Date: 2018-03-12 Impact factor: 8.171
Authors: Wladyslaw Januszewicz; James Hartley; William Waldock; Geoffrey Roberts; Bincy Alias; Anthony Hobson; Lorenz Wernisch; Massimiliano di Pietro Journal: United European Gastroenterol J Date: 2019-10-09 Impact factor: 4.623
Authors: Rena Yadlapati; John E Pandolfino; Alcina K Lidder; Nadine Shabeeb; Diana-Marie Jaiyeola; Christopher Adkins; Neelima Agrawal; Andrew Cooper; Caroline P E Price; Jody D Ciolino; Andrew J Gawron; Stephanie S Smith; Michiel Bove; Bruce K Tan Journal: Am J Gastroenterol Date: 2016-04-19 Impact factor: 10.864
Authors: Rena Yadlapati; Michael Tye; Laurie Keefer; Peter J Kahrilas; John E Pandolfino Journal: Am J Gastroenterol Date: 2017-09-12 Impact factor: 10.864
Authors: Rena Yadlapati; Melina Masihi; C Prakash Gyawali; Dustin A Carlson; Peter J Kahrilas; Billy Darren Nix; Anand Jain; Joseph R Triggs; Michael F Vaezi; Leila Kia; Alexander Kaizer; John E Pandolfino Journal: Gastroenterology Date: 2020-09-16 Impact factor: 22.682